Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Moderna’s mRNA vaccine appears promising for older adults with RSV

January 19, 2023 Research and Development

Moderna’s respiratory syncytial virus (RSV) vaccine has demonstrated positive levels of efficacy in older adults throughout a phase 3 trial. …
News

Neuronetics Inc. announces efficacy of treatment for neurohealth disorders

January 18, 2023 Research and Development

US-based commercial-stage medical technology company Neuronetics Inc., which focuses on designing, developing and marketing products that improve the quality of …
News

Shockwave Medical acquires Neovasc for $100m

January 18, 2023 Research and Development

US-based cardiovascular medical device company Shockwave Medical has signed a deal to acquire specialty medical device company Neovasc for around …
News

Luye Pharma’s Rykindo® approved by FDA for treatment of schizophrenia and bipolar 1 disorder

January 16, 2023 Research and Development

International pharmaceutical company, Luye Pharma, has announced that Rykindo® has received FDA approval for the treatment of schizophrenia in adult …
News

AstraZeneca’s Tezspire gains CHMP approval for the treatment of severe asthma

January 16, 2023 Research and Development

AstraZeneca has announced that Tezspire (also known as tezepelumab) has received approval from the EMA’s Committee for Medicinal Products for …
News

First patient enrolled in Inari DEFIANCE trial for deep vein thrombosis

January 13, 2023 Research and Development

Inari Medical has announced that the first patient has been enrolled in the DEFIANCE trial. This trial will evaluate the …
News

MediciNova completes enrolment for phase 2 clinical trial of ibudilast to treat recurrent and newly diagnosed glioblastoma

January 13, 2023 Research and Development

Biopharmaceutical company MediciNova has announced that its phase 2 clinical trial to assess MN-166 (ibudilast) for the treatment of recurring …
News

Ajinomoto and Exelixis sign agreement to develop novel ADCs for cancer treatment

January 12, 2023 Research and Development

Ajinomoto Co., a Japanese biotech company providing biopharmaceuticals, has signed a license agreement with Exelixis Inc., an oncology-focused biotech company, …
News

Oramed shares disappointing top-line results from phase 3 trial for type 2 diabetes treatment

January 12, 2023 Research and Development

Clinical stage pharmaceutical company, Oramed Pharmaceuticals, has announced top-line results from its phase 3 randomised, double-blind, placebo-controlled, multicentre trial, which …
News

Alvotech’s golimumab biosimilar phase 1 trial begins

January 12, 2023 Research and Development

Alvotech has announced that it has begun a phase 1 study evaluating the safety, tolerability and pharmacokinetics of its golimumab …
News

AbbVie and Anima collaborate for mRNA biology modulators

January 11, 2023 Research and Development

AbbVie and Amina Biotech have announced their collaboration for the discovery and development of mRNA biology modulators focusing on three …
News

FDA grants approval to third-generation VERO Biotech GENOSYL delivery system

January 11, 2023 Research and Development

The FDA has approved US-based medical equipment supplier VERO Biotech’s new-generation tankless inhaled nitric oxide (iNO) delivery system. This new …
News

Day One Biopharmaceuticals to file NDA for paediatric brain cancer treatment before second half of 2023

January 10, 2023 Research and Development

Day One Biopharmaceuticals is set to ask the FDA for approval for tovorafenib before the summer of 2023. Tovorafenib is …
News

FDA approves Eisai-Biogen’s lecanemab for Alzheimer’s disease

January 9, 2023 Research and Development

The FDA has approved Eisai and Biogen’s experimental antibody treatment lecanemab (also known as Leqembi) for the treatment of mild …
News

Island Pharmaceuticals to begin phase 2 trial for dengue prevention and treatment drug

January 5, 2023 Research and Development

It is possible that Island Pharmaceuticals could begin its phase 2a PEACH clinical trial as soon as January 2023. The …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026